Our monthly review of FDA-related news items in the world of cardiology includes updates from CardiacSense, MedAlliance, Lupin, Realize Medical and Eli Lilly and Company.
The finding comes from a new expert consensus statement published by the Society for Cardiovascular Angiography and Interventions. Several industry societies, including the ACC and AHA, have endorsed the document.
The device was first recalled in 2022, but a new software update has now been released that addresses the issue. The FDA wanted a new recall to be issued to ensure all customers went through with the update.
Peter Libby, MD, a cardiovascular medicine specialist with Brigham and Women’s Hospital, discussed the cases of AFib being seen in long-COVID patients.
The firm in question, TRC Capital Investment Corp., has a history of making below-market offers to shareholders of large corporations. These offers are typically unsolicited.
Image courtesy of Dennis et al. and the Journal of the American Heart Association | https://doi.org/10.1161/JAHA.120.016521
While a previous study had found that extracorporeal CPR outperformed conventional CPR among patients with out-of-hospital cardiac arrest, a newer analysis suggests the two treatment options result in similar outcomes.
Schematics showing the exploded view of the wearable imager, with key components labelled (left) and its working principle (right) / Image courtesy of Hu et al. and Nature.
The device, designed to be worn for up to 24 hours at a time, uses ultrasound technology and artificial intelligence to track how much blood the user's heart is pumping.
MIS-C is caused by exposure to the SARS-CoV-2 virus and includes skin rashes and can cause inflammation of the heart and other organs.
In this new video, pediatric cardiologists discuss some of the long-term issues associated with multisystem inflammatory syndrome in children (MIS-C), a rare disease linked to COVID-19.
